SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA ), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024 .
Recent Highlights: Publication of positive AVERT PRETERM TRIAL ( Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls ) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication. Data analysis for final Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outco ME s (PRIME) study begun and database lock anticipated mid-September with goal of publication in time for key pregnancy and maternal health conferences in the spring. Conditional approval received from New York State on ambient whole-blood collection, allowing Sera to complete nationwide rollout of new blood collection method.
Executing variety of cost-effective programs to educate physicians and patients regarding benefits of Sera's PreTRM® Test, such as with a leading platform for U.S. medical professionals with results showing high engagement, a direct to physician multi-channel strategy, and development of social media, email, and broadcast TV strategies to broaden awareness.
"We are pleased to have achieved publication of our positive AVERT study results and look forward to the publication.